Format

Send to

Choose Destination
Transl Androl Urol. 2018 Feb;7(1):155-159. doi: 10.21037/tau.2017.12.26.

Biomarkers in active surveillance.

Author information

1
Department of Urology, New York University, New York, NY, USA.
2
Population Health, New York University, New York, NY, USA.
3
The Manhattan VA, New York, NY, USA.
4
The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Abstract

The use of active surveillance (AS) is increasing for favorable-risk prostate cancer. However, there remain challenges in patient selection for AS, due to the limitations of current clinical staging. In addition, monitoring protocols relying on serial biopsies is invasive and presents risks such as infection. For these reasons, there is substantial interest in identifying markers that can be used to improve AS selection and monitoring. In this article, we review the evidence on serum, urine and tissue markers in AS.

KEYWORDS:

Prostate cancer; active surveillance (AS); biomarkers; markers

Conflict of interest statement

Conflicts of Interest: S Loeb received honoraria for lectures from Astellas, MDxHealth and Boehringer Ingelheim, reimbursed travel from Sanofi and Astellas, and consulting for GE, GenomeDx Biosciences and Lilly (unrelated to the current manuscript). JJ Tosoian has no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center